NVST

Envista Holdings Corp

Add to Watchlist

Advanced Chart

20.240

+0.15(0.747%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

20.3399

Open

20.150

VWAP

20.23

Vol

1.70M

Mkt Cap

3.36B

Low

19.940

Amount

34.35M

EV/EBITDA(TTM)

12.47

Total Shares

171.86M

3.70B

EV/OCF(TTM)

12.66

P/S(TTM)

1.37

Envista Holdings Corporation is a global dental products company. The Company's diversified portfolio of solutions covers a range of dentists' clinical needs for preventing, diagnosing, and treating dental conditions as well as improving the aesthetics of the human smile. It has more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. Its segments include Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segment primarily develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; and endodontic systems and related products.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

651.89M

+5.67%

0.276

+14.83%

684.56M

+4.85%

0.337

+40.31%

639.49M

+6.4%

0.275

+129.5%

Estimates Revision

The market is revising Upward the revenue expectations for Envista Holdings Corporation (NVST) for FY2025, with the revenue forecasts being adjusted by 3.17% over the past three months. During the same period, the stock price has changed by 9.11%.

Revenue Estimates for FY2025

Revise Upward

+3.17%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+11.36%

In Past 3 Month

Stock Price

Go Up

+9.11%

In Past 3 Month

11 Analyst Rating

9.78% Upside

Wall Street analysts forecast NVST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVST is 22.22 USD with a low forecast of 18.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

6 Hold

1 Sell

Moderate Buy

9.78% Upside

Current: 20.240

Low

18.00

Averages

22.22

High

25.00

9.78% Upside

Current: 20.240

Low

18.00

Averages

22.22

High

25.00

Baird

Outperform

maintain

$23 -> $25

2025-08-01

Reason

Baird

Price Target

$23 -> $25

2025-08-01

maintain

Outperform

Reason

Baird raised the firm's price target on Envista to $25 from $23 and keeps an Outperform rating on the shares. The firm updated its model following solid Q2 results driven by solid execution.

Piper Sandler

Neutral

maintain

$17 -> $19

2025-08-01

Reason

Piper Sandler

Price Target

$17 -> $19

2025-08-01

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on Envista (NVST) to $19 from $17 and keeps a Neutral rating on the shares. The firm notes the company reported Q2 results, including revenue of $682M that easily beat the Street's $640M, aided in part by a normalization of demand against easy prior year comps and contributions from a weaker U.S. dollar, but the breadth of strength across segments and geographies was still a relief for dental investors in the wake of the more guarded demand commentary from peer Align Technology (ALGN).

Mizuho

Underperform

maintain

$15 -> $18

2025-08-01

Reason

Mizuho

Price Target

$15 -> $18

2025-08-01

maintain

Underperform

Reason

Mizuho raised the firm's price target on Envista to $18 from $15 and keeps an Underperform rating on the shares. The company reported double-digit year-over-year sales growth for its Spark clear aligner franchise, the analyst tells investors in a research note.

UBS

Kevin Caliendo

Neutral

maintain

$18 -> $22

2025-07-29

Reason

UBS

Kevin Caliendo

Price Target

$18 -> $22

2025-07-29

maintain

Neutral

Reason

UBS analyst Kevin Caliendo raised the firm's price target on Envista to $22 from $18 and keeps a Neutral rating on the shares.

Leerink

Market Perform

maintain

2025-07-14

Reason

Leerink

Price Target

2025-07-14

maintain

Market Perform

Reason

Leerink raised the firm's price target on Envista to $21.50 from $18.50 and keeps a Market Perform rating on the shares. Heading into Q2 earnings, the firm is updating dental company estimates and publishing the results of its fourth semi-annual dental survey of 63 dental practitioners in the United States. There is clearly a budding interest in identifying incremental improvements across the dental space, even if each opportunity seems to be company-specific in what remains a still-challenged total dental end-market, Leerink says. The firm sees reasons to be positive on each stock in its coverage but also has some offsetting questions that limit too much constructiveness.

Baird

Jeff Johnson

Neutral -> Outperform

upgrade

$21 -> $23

2025-05-27

Reason

Baird

Jeff Johnson

Price Target

$21 -> $23

2025-05-27

upgrade

Neutral -> Outperform

Reason

Baird analyst Jeff Johnson upgraded Envista to Outperform from Neutral with a price target of $23, up from $21. Baird's May domestic dental survey notably improved following bad April findings, the analyst tells investors in a research note. The firm says its feedback consistently points to stable to slightly improved dental demand last couple months, including in the U.S., but not to extent of the sequential inflection seen in this month's survey. It sees revenue and earnings upside for Envista in 2025 and 2026. Stable end markets and the recent China tariff relief will likely help this upside become increasingly apparent over the next couple quarters, contends Baird.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Envista Holdings Corp (NVST.N) is 17.14, compared to its 5-year average forward P/E of 20.63. For a more detailed relative valuation and DCF analysis to assess Envista Holdings Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

20.63

Current PE

17.14

Overvalued PE

24.70

Undervalued PE

16.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

13.23

Current EV/EBITDA

10.12

Overvalued EV/EBITDA

15.47

Undervalued EV/EBITDA

11.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

1.95

Current PS

1.25

Overvalued PS

2.49

Undervalued PS

1.40